Scholar IQ
Try ScholarIQ free
Upload Records Snowball Search Search OpenAlex
About the database
On this page:OverviewPublicationsResearchersInstitutionsOpen access
ScholarIQanswers from OpenAlex

Novo Nordisk (Denmark)

InstitutionResearch output, impact & collaborations

Novo Nordisk (Denmark) is a research organisation in Copenhagen, DK. OpenAlex records 13,546 works and 1,516,992 citations for it. 3,664 researchers list it as their most recent affiliation.

13,546
Works
1,516,992
Citations
3,664
Researchers
35.4
Avg h-index

How has Novo Nordisk (Denmark)'s publication output changed over time?

ScholarIQpublication output · 2013–2024

Output grew0% over the shown period — from 1 works in 2013 to 1 in 2024.

1
1
2
1
1
3
2
1
20132014201520182019202120232024

Who are the most-cited researchers behind Novo Nordisk (Denmark)?

ScholarIQtop researchers by citations
1
Ole Kleist Jeppesen · Diabetes Treatment and Management
53 works5,587 citations
2
S. B. Andersen · Plant tissue culture and regeneration
129 works4,038 citations
3
Florian M.M. Baeres · Diabetes Treatment and Management
40 works3,575 citations
4
Manuel Mayrdorfer · Renal Transplantation Outcomes and Treatments
33 works620 citations
5
Charlotte Bisgaard · Schizophrenia research and treatment
14 works331 citations

What are the most-cited papers on Novo Nordisk (Denmark)?

ScholarIQmost cited works
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
Stefan D. Anker, Javed Butler, Gerasimos Filippatos, João Pedro Ferreira, Edimar Alcides Bocchi, Michael Böhm, Hans‐Peter Brunner‐La Rocca, Dong‐Ju Choi, Vijay Chopra, Eduardo Chuquiure‐Valenzuela, Nadia Giannetti, Juan Esteban Gómez‐Mesa, Stefan Janssens, James L. Januzzi, José Ramón González‐Juanatey, Béla Merkely, Stephen J. Nicholls, Sergio V. Perrone, Ileana L. Piña, Piotr Ponikowski, Michele Senni, David Sim, Jindřich Špinar, Iain Squire, Stefano Taddei, Hiroyuki Tsutsui, Subodh Verma, Dragoş Vinereanu, Jian Zhang, Peter E. Carson, Carolyn S.P. Lam, Nikolaus Marx, Cordula Zeller, Naveed Sattar, Waheed Jamal, Sven Schnaidt, Janet Schnee, Martina Brueckmann, Stuart Pocock, Faı̈ez Zannad, Milton Packer
New England Journal of Medicine. 20214,718 CitationsOPEN ACCESS
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
A. Michael Lincoff, Kirstine Brown‐Frandsen, Helen M. Colhoun, John Deanfield, Scott S. Emerson, Sille Esbjerg, Søren Hardt‐Lindberg, G. Kees Hovingh, Steven E. Kahn, Robert F. Kushner, Ildiko Lingvay, Tuğçe Kalaycı Oral, Marie Mide Michelsen, Jorge Plutzky, Christoffer W. Tornøe, Donna H. Ryan
New England Journal of Medicine. 20232,815 CitationsOPEN ACCESS
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society
Børge G. Nordestgaard, M. John Chapman, Steve E. Humphries, Henry N. Ginsberg, L. Masana, Olivier Descamps, Olov Wiklund, Robert A. Hegele, Frederick J. Raal, Joep C. Defesche, Albert Wiegman, Rodrigo da Silva Santos, Gerald F. Watts, KG Parhofer, G. Kees Hovingh, Petri T. Kovanen, Cathérine Boileau, Maurizio Averna, Jan Borén, E. Bruckert, Alberico L. Catapano, Jan Albert Kuivenhoven, P. Pajukanta, Kausik K. Ray, A.F.H. Stalenhoef, Erik S.G. Stroes, Marja‐Riitta Taskinen, Anne Tybjærg‐Hansen, for the European Atherosclerosis Society Consensus Panel
European Heart Journal. 20132,762 CitationsOPEN ACCESS
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Mansoor Husain, Andreas L. Birkenfeld, Morten Donsmark, Kathleen Dungan, Freddy G. Eliaschewitz, Denise Reis Franco, Ole Kleist Jeppesen, Ildiko Lingvay, Ofri Mosenzon, Sue D. Pedersen, Cees J. Tack, Mette S. Thomsen, Tina Vilsbøll, Mark Warren, Stephen C. Bain
New England Journal of Medicine. 20191,969 CitationsOPEN ACCESS
Cardiovascular Disease in Chronic Kidney Disease
Joachim Jankowski, Jürgen Floege, Danilo Fliser, Michael Böhm, Nikolaus Marx
Circulation. 20211,872 CitationsOPEN ACCESS

How much of the research on Novo Nordisk (Denmark) is open access?

ScholarIQopen access share
92%OPEN ACCESS
Gold
0%
Green
17%
Hybrid
42%
Bronze
33%
Closed
8%

Related on ScholarIQ

Diabetes Treatment and Management
Top Topic
Diabetes Management and Research
Top Topic
Pancreatic function and diabetes
Top Topic
Hemophilia Treatment and Research
Top Topic
Metabolism, Diabetes, and Cancer
Top Topic
Diabetes, Cardiovascular Risks, and Lipoproteins
Top Topic
470M+ articles · free account